MARKET

CLSN

CLSN

Celsion
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.890
-0.130
-4.30%
After Hours: 2.950 +0.06 +2.08% 19:43 05/27 EDT
OPEN
2.940
PREV CLOSE
3.020
HIGH
3.200
LOW
2.760
VOLUME
2.58M
TURNOVER
--
52 WEEK HIGH
3.650
52 WEEK LOW
0.6865
MARKET CAP
84.55M
P/E (TTM)
-3.3770
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLSN stock price target is 7.50 with a high estimate of 9.00 and a low estimate of 4.000.

EPS

CLSN News

More
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday, 118 companies set new 52-week highs.
Benzinga · 1d ago
71 Biggest Movers From Friday
Gainers Inari Medical, Inc. (NASDAQ: NARI) shares surged 123.7% to close at $42.51 on Friday after pricing its IPO on Friday.
Benzinga · 1d ago
46 Stocks Moving In Friday's Mid-Day Session
Gainers Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) shares jumped 98.40% to $2.5201 after the company announced positive preliminary results from the second interim analysis of its ongoing NAV3-31 Phase 2B study.
Benzinga · 5d ago
ZYNE, CLSN, SNCA and SNDX among midday movers
Seeking Alpha - Article · 5d ago
Stocks That Hit 52-Week Highs On Friday
On Friday, 46 stocks hit new 52-week highs.
Benzinga · 5d ago
Mid-Morning Market Update: Markets Fall; Alibaba Earnings Beat Estimates
Following the market opening Friday, the Dow traded down 0.64% to 24317.72 while the NASDAQ fell 0.21% to 9265.84. The S&P also fell, dropping 0.42% to 2936.06.
Benzinga · 5d ago
PANW, SPLK among premarket gainers
Seeking Alpha - Article · 5d ago
30 Stocks Moving in Friday's Pre-Market Session
Gainers Navidea Biopharmaceuticals, Inc. (NASDAQ: NAVB) shares rose 65.2% to $2.18 in pre-market trading after the company reported results of second interim analysis of ongoing Phase 2B study in rheumatoid arthritis.
Benzinga · 5d ago

Industry

Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Symbol
Price
%Change

About CLSN

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
More

Webull offers kinds of Celsion Corporation stock information, including NASDAQ:CLSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSN stock news, and many more online research tools to help you make informed decisions.